Engagement of NKG2D by their ligands (NKG2D-L), as the human major histocompatibility complex class I-related molecules MIC-A and the UL16-binding proteins, on cytolytic lymphocytes leads to the enhancement of antitumour effector functions. These ligands are missing or expressed at very low levels on leukaemic cells; furthermore, they can be shed by tumour cells and inhibit cytolytic activity of lymphocytes. Herein, we show that in vivo administration of all-trans-retinoic acid (ATRA) or the histone deacetylase inhibitor sodium valproate (VPA) to patients affected with acute myeloid leukaemia (AML) M3 or M1 respectively, leads to the induction of transcription and expression of NKG2D-L at the surface of leukaemic cells. Apparently, no detectable shedding of the soluble form of these molecules was found in patients' sera. Conversely, AML blasts from patients treated with chemotherapy not including ATRA or VPA did not show any induction of NKG2D-L transcription. Furthermore, upon therapy with ATRA or VPA, leukaemic blasts become able to trigger lytic granule exocytosis by autologous CD8 þ T and natural killer lymphocytes, as shown by CD107a mobilization assay, followed by leukaemic cell lysis. These findings indicate that ATRA and VPA may contribute to the activation of cytolytic effector lymphocytes in vivo, possibly enhancing their anti-leukaemic effect.
Introduction
The human major histocompatibility complex class I-related molecules MIC-A expressed by transformed cells, the UL16-binding proteins (ULBPs) and MIC-B molecules, which bind to the cytomegalovirus glycoprotein UL16, [1] [2] [3] are ligands for the natural killer (NK) cell receptor NKG2D (NKG2D-L) expressed by effector lymphocytes. [4] [5] [6] [7] Engagement of NKG2D by these ligands leads to the activation of CD8 þ T lymphocytes through the induction of degranulation and cytolytic activity. [1] [2] [3] [4] [5] [6] [7] Evidence has been provided that both T and NK cells can recognize MIC-A and MIC-B expressed by intestinal epithelial cells, and that several epithelial cancers are infiltrated by lymphocytes that kill MIC-A-or MIC-B-expressing tumour cells. 1, 2 Recently, also tumours expressing ULBP1, ULBP2 or ULBP3 have been reported to stimulate cytotoxic activity of immune cells. 8, 9 Unfortunately, all these molecules are undetectable or expressed at very low levels on leukaemic cells, [10] [11] [12] although they can be upregulated in vitro by retinoic acid or by the histone-deacetylase inhibitor sodium valproate (VPA). [13] [14] [15] [16] [17] In particular, we reported that in chronic lymphocytic leukaemia patients, upon in vitro induction of transcription and expression of MIC-A or ULBP3 on leukaemic cells by alltrans-retinoic acid (ATRA), a subset of gd T lymphocytes proliferate and kill autologous tumour cells. 18 Likewise, ULBP2 þ and ULBP3 þ tumour cells from non-Hodgkin's lymphoma patients induced proliferation and cytokine production by gd T lymphocytes by triggering the NKG2D molecule. 9 In both chronic lymphocytic leukaemia and non-Hodgkin's lymphoma, patients with high expression of ULBPs on cancer cells and undetectable soluble molecules in their sera showed stable disease in a 1-year follow-up, at variance with patients with undetectable ULBPs, but high levels of serum-soluble molecules. 9, 18 It has been reported that the induction of NKG2D-L on acute myeloid blasts upon in vitro exposure to VPA correlates with an increased susceptibility to lysis of leukaemic blasts exerted by NK cells. 16 On the basis of these data, we addressed the question of whether in vivo administration of ATRA or VPA can induce the upregulation of NKG2D-L expression at the surface of myeloid leukaemic cells, thus leading to autologous effector lymphocyte activation.
Materials and methods

Patients
Sixteen patients with acute myeloid leukaemia (AML), ten M1 and six M3 according to the French-American-British classification were studied at the Department of Haematology, University of Genoa. Peripheral blood (PB) and bone marrow (BM) samples were drawn, under conventional diagnostic procedures, from patients before and at days 0, 1, 3, 5, 7 and 21 after therapy, upon informed consent and IRB approval. Clinical features and therapies for each patient are summarized in Table 1 . Briefly, the six M3 patients were treated with the MY-AIDA scheme of therapy; among M1 patients, four underwent MY-FLAI therapy, four AZA-VPA, while two high-risk AML patients not eligible for intensive therapy were treated with VPA alone (Table 1) .
Isolation of leukaemic blasts and PB mononuclear cells
Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation on days 0, 1, 3, 5, 7 of chemotherapy to obtain leukaemic blasts, and on day 21 after therapy to obtain PBMC lacking leukaemic cells. Leukaemic cells were purified by depletion of T and B lymphocytes using immunomagnetic beads (EasySep Mo cell enrichment kit, StemCell Technologies, Vancouver, CA, USA) and were 498% pure as assessed by CD33 staining, and they were frozen till their use in functional experiments. In some cases, NK cells were derived from PBMCs as described. 18 Briefly, red cells were recovered, washed twice and then added to autologous PBMCs at 30:1 ratio; purification was performed with the RosetteSep NK cell enrichment kit (StemCell Technologies). NK cells were 498% pure as assessed by CD16 staining.
Quantitative real-time PCR
RNA was extracted from AML cells with TriPure (Roche Diagnostics, Milan, Italy) and reverse transcribed with random primers. Primers and probes for MIC-A, MIC-B, ULBP1, ULBP2, ULBP3 and ULBP4 were designed using the PrimerExpress software (Applied Biosystems, Foster City, CA, USA). Quantitative real-time PCR (Q-RT-PCR) was performed on the 7900HT FastRT-PCR system (Applied Biosystems) with the fluorescent Taqman method. 19 MIC-A, MIC-B, ULBP1, ULBP2, ULBP3 and ULBP4 mRNAs were normalized to GUS as a control gene and were referred to a standard curve, that is, serial dilutions of plasmids containing cloned sequences of GUS (Ipsogen, Marseille, France). After subtracting the threshold cycle (C T ) value for GUS from the C T values of the target genes, the DC T values were converted with the formula 2
ÀDDCT to show the foldrelative increase in MIC-A, ULBP2 and ULBP3 mRNA expression compared with the levels before treatment, which were given the arbitrary value of 1.
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ELISA for MIC-A and ULBPs
Soluble (s)MIC-A, sULBP2 and sULBP3 were measured in patients' sera by ELISA (enzyme-linked immunosorbent assay) as described. 18, 21 The anti-MIC-A mAbs AMO1 and BAMO3 were from Immatics Biotechnologies (Tubingen, Germany) and the anti-ULPBs mAbs (anti-ULBP2 M311, IgG1; anti-ULBP3 M551, IgG1) were provided by Amgen (Seattle, WA, USA). The anti-ULBP2 and anti-ULBP3 detection mAbs (MAB1298, IgG2a; MAB15171, IgG2a) were from R&D System (Minneapolis, MN, USA). Anti-mouse IgG2a HRP was from Southern Biotechnology Associates (Birmingham, AL, USA). Plates were developed with 2,2 0 -azinobis(2-ethylbenzothiazoline-6-sulfonic acid) (Sigma Chemicals Co., St Louis, MO, USA) and read at OD 450 nm . Results are expressed as ng/ml and referred to a standard curve obtained with the MIC-A/Fc, ULPB2/Fc or ULBP3/Fc chimeras (R&D System).
Cytofluorometric analysis
Immunofluorescence was performed with the anti-NKG2D-L mAbs (MIC-A, ULBPs) labelled with the Alexafluor 488 (Zenon Tricolor Labeling Kit, Molecular Probes Europe, Leiden, The Netherlands). Leukaemic blasts were identified on the basis of 
CD107a mobilization assay
To evaluate cell-mediated cytotoxicity, we performed a CD107a, the lysosome-associated protein LAMP-1, mobilization assay. 22, 23 The expression at the cell surface of CD107a directly correlates with the degree of degranulation by cytolytic effector cells and with lysis of target cells. 23 Briefly, PBMC or NK cells from AML patients were cultured for 3 days in the presence of recombinant IL15 (rIL15, 20 ng/ml, PeproTec EC, London, UK), and tested for cytotoxic granule exocytosis against autologous leukaemic cells, obtained before and 3 days after ATRA or VPA administration, by CD107a surface expression. 22 NK cells were also purified from AML patients by immunomagnetic beads (Stem Cell Biotechnology), cultured as above and tested for cytotoxic activity against autologous leukaemic cells. Briefly, PBMC or NK cells were co-incubated with autologous leukaemic cells for 2 h, at the effector/target (E:T) ratio of 5:1, then stained with the PE-conjugated anti-CD107a mAb (Becton Dickinson). This optimal E:T ratio and time of co-incubation were determined by preliminary experiments performed at the In Cytolytic assay. The classical labelling with 51 Cr of primary leukaemic cells was not efficient. Thus, a cytolytic assay using a different probe for labelling target cell was applied. The DELFIA EuTDA cytotoxicity reagents have been used (PerkinElmer, Wellesley, MA, USA) following the manufacture's instruction. Briefly, leukaemic cells were labelled with bis-acetoxymethyl Figure 3 CD107a mobilization in autologous CD3 þ CD8 þ T lymphocytes upon interaction with myeloid leukaemic blasts. Peripheral blood mononuclear cells (PBMC) cultured with IL15 (20 ng/ml) for 3 days were incubated with autologous leukaemic blasts either before (a) or after (b) in vivo administration of ATRA. IL15-activated PBMCs and leukaemic blasts were just mixed together (to) (a and b, upper displays) or co-incubated for 2 h (t2 h) in the absence (a and b, central row displays). In a limited number of cases (n ¼ 2 M3 and n ¼ 2 M1) this experiment has been performed also in the presence of anti-NKG2D mAb (2 mg/ml), (a and b, lower displays). Cells were harvested and stained with FITC-anti-CD8 mAb and PerCP-anti-CD3 mAb and PE-anti-CD107a mAb. To determine the percentage of CD107a þ T lymphocytes a first gate (R1) set on physical parameters as forward scatter (FSC, arbitrary units, a.u.) and side scatter (SSC, a.u.) on small cells corresponding to lymphocytes was performed (left dot plots), then a second gate (R2) defining CD3 þ CD8 þ T lymphocytes was carried out (central dot plots). The expression of CD107a was analysed combining gate R1 and R2 (right hystograms). In vivo induction of NKG2D ligands by ATRA or VPA A Poggi et al 2,2 0 ,6 0 ,2 00 -terpyridine-6,6 00 -dicarboxylate (BA-TDA) (1 ml/1 Â 10 6 cells/ml) for 20 min at 37 1C, extensively washed and then added to 96-well round bottomed plates together with autologous effector lymphocytes at different E:T ratio from 20:1 to 1:1 either in the presence or absence of anti-NKG2D mAb (clone 149810, from R&D Systems Inc.) and/or a mixture of anti-NKG2DL mAbs (anti-MICA, anti-ULBP2 and anti-ULBP3) or control mAb of the same isotype (anti-CD8 mAb, clone astra102 for PBMC or anti-CD56 mAb, clone leu19 (Becton Dickinson) for NK cells) all at the final concentration of 2 mg/ml. After 2 h, 20 ml of supernatant from each well of the cytotoxic assay were transferred to flat-bottomed plates and 200 ml of Europium solution was added. The fluorescence emitted by the binding of Europium with the ligand TDA was analysed by the time-resolved fluorometer VICTOR 2 (PerkinElmer). The % of specific release was calculated applying the following formula: experimental release (counts)Àspontaneous release (counts)/maximum release (counts)Àspontaneous release (counts). Maximum and spontaneous release were calculated accordingly to the manufacture's instruction. The validity of this cytolytic assay was assessed by performing the labelling with BA-TDA of leukaemic tumour cell lines (Jurkat, K562, MM6, U937 and HL-60) and evaluating cytolysis in comparison with parallel experiments performed by labelling the same tumour cells with 51 Cr. We found that the % of specific lysis of a given tumour cell lines by effector lymphocytes was superimposable by using the two different labelling (not shown).
Statistical analysis
Statistical analysis was performed by analysis of variance and by Student's t-test.
Results and discussion
Induction of NKG2D-L on leukaemic cells upon administration of ATRA or VPA Six AML M3 patients (patients 1-6 of Table 1 ) underwent MY-AIDA cycle of therapy; four AML M1 patients were treated with MY-FLAI (patients 7-10), four with AZA-VPA (patients [11] [12] [13] [14] and two with VPA alone (patients [15] [16] . PB samples, for both cell separation and sera, were drawn before (day 0) and at the indicated time points of therapy (days 1, 3, 5, 7) and on day 21 to obtain PB lymphocytes lacking leukaemic blasts. Leukaemic blasts, according to cell size, based on larger forward scatter and side scatter than lymphocytes, evaluated by cytofluorimetric analysis and morphology analysed by microscopic examination of blood smears, ranged between 80 and 90% before therapy, 50 and 60% on day 1, 30-40% on day 3, 20-30% on day 5 and 5-10% on day 7. Q-RT-PCR, performed on leukaemic blasts purified as described (see Materials and methods), showed that transcription of MIC-A was induced 24 h after administration of ATRA to AML M3 patients, or after VPA treatment in AML M1 patients, and lasted up to day 7 ( Figure 1a, left panel) . ULBP2 transcription started by day 1 as well and showed a maximum increase at day 3 for both treatments (Figure 1a, middle panel) . ULBP3 showed a similar kinetics of induction in response to VPA or ATRA administration (Figure 1a, right panel) . Conversely, no significant increase in ULBP1 or ULBP4 transcription was found after either therapy (not shown). Of note, in the two patients who underwent therapy with VPA alone, transcription of MIC-A, ULBP2 and ULBP3 was observed (Figure 1b) , supporting that this drug is indeed responsible for NKG2D-L induction. Along this line, AML blasts from patients treated with MY-FLAI (that includes fludarabine, ara-C and idarubicine as MY-AIDA, but not ATRA) did not show any induction of NKG2D-L transcription (Figure 1b) ruling out the possibility that these drugs mediated the effect observed in patients treated with MY-AIDA, rather due to ATRA (Figure 1a) .
We further analysed the effect of ATRA or VPA therapy on the expression of NKG2D-L at the surface of leukaemic blasts. Figure 2a shows that expression of MIC-A (left panel), ULBP2 (central panel) and ULBP3 (right panel) is strongly induced on leukaemic cells, identified by double immunofluorescence staining with anti-CD33 and anti-MIC-A or anti-ULBP2 or ULBP3 mAbs, and by the larger forward scatter and side scatter than lymphocytes by day 3 of VPA or ATRA administration, and all NKG2D-L are detectable up to day 7 (Figure 2a ). After this time point, the percentage of blasts (always o2%) was not sufficient to allow further evaluation of NKG2D-L expression (not shown). Again, the effect of VPA was evident also in leukaemic cells from patients treated with VPA alone (Figure 2b) .
It has been reported that soluble (s) forms of MIC-A and ULBPs can be released by tumour cells and impair the function of CD3 þ CD8 þ cytotoxic T lymphocytes and NK cells. 21, 24, 25 Moreover, serum levels of sMIC-A and sULBPs have been In vivo induction of NKG2D ligands by ATRA or VPA A Poggi et al proposed to be associated with disease progression in solid tumours, chronic lymphocytic leukaemia and multiple myeloma. 18, 21, 24 Thus, we measured sMIC-A, sULBP2 and sULBP3 in patients' serum obtained before and during VPA or ATRA administration. Of note, serum levels of either NKG2D-L did not vary upon VPA or ATRA treatment ( Figure 2c) ; nevertheless, at variance with sULBP2 (middle panel) and sULBP3 (right panel), sMIC-A was detectable in the serum of AML patients and decreased after therapy (left panel), together with the reduction of leukaemic cells.
Degranulation of autologous effector cells by leukaemic blasts upon induction of NLG2D-L
To verify whether the upregulation of NKG2D-L on leukaemic blasts could lead to the activation of cytolytic effector cells, we analysed the degree of degranulation of cytotoxic vesicles by the evaluation of surface expression of CD107a. This assay enables rapid assessment of cell-mediated cytotoxicity through sensitive detection of CD107a, the lysosome-associated protein LAMP-1, exposed on the cell surface after interaction with target cells and subsequent secretion of lytic granule contents such as perforins and granzymes. 22, 23 Thus, PBMCs were isolated from AML patients after the induction cycle when remission was achieved and cultured for 3 days with rIL15. IL15-activated PBMC were then co-incubated with autologous leukaemic blasts obtained at diagnosis (day 0, Figures 3a and 4a, b) or on day 3 of ATRA or VPA therapy (Figures 3b and 4a, b) . On time 0 (basal conditions, t0) and after 2 h (t2 h) of co-incubation, to identify cytolytic T lymphocytes that had degranulated cytotoxic vesicles, samples were triple stained with PE-conjugated anti-CD107a mAb, and with FITC-conjugated anti-CD8 mAb together with PerCP-anti-CD3 mAb. A representative experiment is depicted in Figure 3 and the results obtained with all the patients analysed are summarized in Figure 4 . CD3 þ CD8 þ T cells did not express, as expected, CD107a at their surface just after co-incubation with AML blasts (Figures 3a and b, right upper panels) . A small percentage of CD8 þ T cells (range 5-15%, n ¼ 6) expressed CD107a at the cell surface when co-incubated for 2 h with AML blasts lacking surface expression of NKG2D-L (Figure 3a: central right panel and Figures 4a and b) . Of note, the percentage of CD107a þ CD8 þ T lymphocytes strongly increased (range 38-50%, n ¼ 6) upon interaction with NKG2D-L þ AML M3 blasts isolated from patients treated with ATRA (Figure 3b : central right panel and Figure 4a ) or with NKG2D-L þ AML M1 leukaemic cells after VPA administration (range 35-40%, n ¼ 6) (Figure 4b) . Importantly, the increment of CD107a surface expression on CD3 þ CD8 þ lymphocytes detected upon interaction with NKG2DL þ AML M3 blasts, in vivo treated with ATRA, was almost abolished when anti-NKG2D mAbs were added to the In vivo induction of NKG2D ligands by ATRA or VPA A Poggi et al degranulation assay (Figure 3b, lower panels) . Likewise, IL15-activated CD8 þ T lymphocytes, IL15-activated CD16 þ NK cells expressed CD107a at the cell surface only after co-incubation with AML blasts (10-22%, n ¼ 4 compared with basal level of 5-7%, Figure 4c ; 7-15% compared with basal level of 2-8%, Figure 4d ). The percentage of CD107a þ cells strongly increased when CD16 þ NK cells were co-incubated with M3 or M1 leukaemic cells obtained after in vivo treatment with ATRA (35-43%, n ¼ 4, Figure 4c ) or VPA, respectively (38-48%, n ¼ 4, Figure 4c ).
NKG2D/NKG2D-L interaction is responsible for the recognition of leukaemic blasts by autologous effector cells
In evaluating activation of cytolysis in effector lymphocytes, we were not successful in performing a classical 51 Cr release cytolytic assay, as primary leukaemic cells were not efficiently labelled (not shown). Thus, we used a cytolytic assay using the BA-TDA probe for labelling primary leukaemic cells (see Materials and methods section). As shown in Figure 5 , we found that M3 or M1 leukaemic cells, obtained after in vivo treatment with ATRA or VPA, respectively, were more efficiently lysed by IL15-activated PBMCs (panels a and c) or IL15-activated NK cells (panels b and d) (a fivefold increase approximately), than AML blasts isolated from the same patients before drug treatment. Importantly, the addition of anti-NKG2D mAb or a mixture of anti-NKG2D-L (anti-MICA, anti-ULBP2 and anti-ULBP3) mAb, alone or in combination, to the cytolytic assay strongly reduced the lysis of autologous leukaemic cells (70-95% of reduction) (Figures 5a-d) . These findings would support the notion that NKG2D/NKG2D-L interaction is responsible for the recognition of leukaemic blasts after in vivo treatment with ATRA or VPA.
In conclusion, we provided evidence that upregulation of NKG2D-L on leukaemic cells can occur in vivo upon therapy with ATRA or VPA, supporting the hypothesis that drug-treated blasts may lead to the activation of NKG2D þ autologous cytotoxic lymphocytes. This is of interest as enhancement of effector cell function through the recognition of NKG2D-L on tumour cells has been proposed in multiple myeloma treatment; 24 the administration of ATRA or VPA in acute leukaemias may contribute to this mechanism, besides inducing leukaemic cell maturation.
